Cynapsus releases clinical trial data about its sublingual thin-film strip for Parkinson's

Cynapsus Therapeutics touted the results of its Phase 2 clinical trial of its sublingual thin-film-strip formulation of apomorphine for the management of OFF motor symptoms of Parkinson's disease. "These preliminary data show that APL-130277 was able to convert patients from a severe OFF state in the morning to ON. In addition, treatment was associated with a 45% improvement in motor function based on the change in [Unified Parkinson's Disease Rating Scale] part III from baseline. The mean dose needed to terminate the OFF episode was 18.4 mg. In addition, those patients achieving a response at higher doses appeared to adapt to the treatment, as seen by the lack of nausea at higher doses," said Dr. Albert Agro, chief medical officer of Cynapsus. Release

Suggested Articles

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.

Researchers at Johns Hopkins have changed the structure of a new cancer drug to allow it to more easily pass the blood-brain barrier, giving it access to…

Medtronic’s world-first FDA-approved hybrid closed-loop insulin delivery system might soon face competition, as T1D Exchange has pledged to invest in the…